Anti-CD79a Antibody (RMAB-0250407)
Cat. No.: RMAB-0250407
Category: Primary Antibodies
INQUIRY
100 μL
Customer Size
Rabbit monoclonal to CD79a
Product Features
| Isotype | IgG |
|---|---|
| Clonality | Monoclonal |
| Host Species | Rabbit |
| Clone Number | EPR3619 |
| Form | Liquid |
| Purity | Protein A purified |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide. |
| Applications | WB, Flow Cyt |
| Key Features | Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply; Rabbit monoclonal to CD79a; Suitable for: WB, Flow Cyt; Knockout validated; Reacts with: Human |
Target Information
| Target Symbol | CD79A |
|---|---|
| Target Name | B-cell antigen receptor complex-associated protein alpha chain |
| UniProt ID | P11912 |
| Cellular Localization | Cell membrane. Following antigen binding, the BCR has been shown to translocate from detergent-soluble regions of the cell membrane to lipid rafts although signal transduction through the complex can also occur outside lipid rafts. |
| Function | Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B cells. |
| Involvement in Disease | Defects in CD79A are the cause of agammaglobulinemia type 3 (AGM3). It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life. Two different mutations, one at the splice donor site of intron 2 and the other at the splice acceptor site for exon 3, have been identified. Both mutations give rise to a truncated protein. |
| Post-translational Modifications | Phosphorylated on tyrosine, serine and threonine residues upon B-cell activation. Phosphorylation of tyrosine residues by Src-family kinases is an early and essential feature of the BCR signaling cascade. The phosphorylated tyrosines serve as docking sites for SH2-domain containing kinases, leading to their activation which in turn leads to phosphorylation of downstream targets. Phosphorylation of serine and threonine residues may prevent subsequent tyrosine phosphorylation. |
| Sequence Similarities | Contains 1 Ig-like C2-type (immunoglobulin-like) domain. Contains 1 ITAM domain. |
Storage & Shipping
| Storage Buffer | pH: 7.2; Preservative: 0.05% Sodium azide; Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant |
|---|---|
| Storage & Shipping | Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. |
For research use only. Not for clinical use.
